Immunobiology of chronic lung allograft dysfunction

New insights from the bench and beyond

R. A. Shilling, D. S. Wilkes

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The first successful human lung transplants were performed in the 1980s. Since that time lung transplantation has been a therapeutic modality for end-stage pulmonary diseases. However, chronic rejection, known as obliterative bronchiolitis (OB)/bronchiolitis obliterans syndrome (BOS), is the key reason why the 5-year survival is only 50%, which is significantly worse than most other solid organ transplants. Recent studies have provided exciting advances that are beginning to be translated into findings in humans. This review will highlight the current advances in understanding the mechanisms of OB/BOS in lung transplant recipients.

Original languageEnglish
Pages (from-to)1714-1718
Number of pages5
JournalAmerican Journal of Transplantation
Volume9
Issue number8
DOIs
StatePublished - Aug 2009

Fingerprint

Bronchiolitis Obliterans
Bronchiolitis
Allografts
Transplants
Lung
Lung Transplantation
Lung Diseases
Survival
Therapeutics
Transplant Recipients

Keywords

  • Alloimmunity
  • Autoimmunity
  • Bronchiolitis obliterans syndrome
  • IL-17
  • Lung transplantation
  • Obliterative bronchiolitis

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Immunobiology of chronic lung allograft dysfunction : New insights from the bench and beyond. / Shilling, R. A.; Wilkes, D. S.

In: American Journal of Transplantation, Vol. 9, No. 8, 08.2009, p. 1714-1718.

Research output: Contribution to journalArticle

@article{6d67a67835d14d0a83a41db948a36f5d,
title = "Immunobiology of chronic lung allograft dysfunction: New insights from the bench and beyond",
abstract = "The first successful human lung transplants were performed in the 1980s. Since that time lung transplantation has been a therapeutic modality for end-stage pulmonary diseases. However, chronic rejection, known as obliterative bronchiolitis (OB)/bronchiolitis obliterans syndrome (BOS), is the key reason why the 5-year survival is only 50{\%}, which is significantly worse than most other solid organ transplants. Recent studies have provided exciting advances that are beginning to be translated into findings in humans. This review will highlight the current advances in understanding the mechanisms of OB/BOS in lung transplant recipients.",
keywords = "Alloimmunity, Autoimmunity, Bronchiolitis obliterans syndrome, IL-17, Lung transplantation, Obliterative bronchiolitis",
author = "Shilling, {R. A.} and Wilkes, {D. S.}",
year = "2009",
month = "8",
doi = "10.1111/j.1600-6143.2009.02690.x",
language = "English",
volume = "9",
pages = "1714--1718",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Immunobiology of chronic lung allograft dysfunction

T2 - New insights from the bench and beyond

AU - Shilling, R. A.

AU - Wilkes, D. S.

PY - 2009/8

Y1 - 2009/8

N2 - The first successful human lung transplants were performed in the 1980s. Since that time lung transplantation has been a therapeutic modality for end-stage pulmonary diseases. However, chronic rejection, known as obliterative bronchiolitis (OB)/bronchiolitis obliterans syndrome (BOS), is the key reason why the 5-year survival is only 50%, which is significantly worse than most other solid organ transplants. Recent studies have provided exciting advances that are beginning to be translated into findings in humans. This review will highlight the current advances in understanding the mechanisms of OB/BOS in lung transplant recipients.

AB - The first successful human lung transplants were performed in the 1980s. Since that time lung transplantation has been a therapeutic modality for end-stage pulmonary diseases. However, chronic rejection, known as obliterative bronchiolitis (OB)/bronchiolitis obliterans syndrome (BOS), is the key reason why the 5-year survival is only 50%, which is significantly worse than most other solid organ transplants. Recent studies have provided exciting advances that are beginning to be translated into findings in humans. This review will highlight the current advances in understanding the mechanisms of OB/BOS in lung transplant recipients.

KW - Alloimmunity

KW - Autoimmunity

KW - Bronchiolitis obliterans syndrome

KW - IL-17

KW - Lung transplantation

KW - Obliterative bronchiolitis

UR - http://www.scopus.com/inward/record.url?scp=67650932113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650932113&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2009.02690.x

DO - 10.1111/j.1600-6143.2009.02690.x

M3 - Article

VL - 9

SP - 1714

EP - 1718

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 8

ER -